PHOENIX—Trinity Capital Inc. (NASDAQ: TRIN), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $45 million in growth capital to Neurolens, a company commercializing innovative solutions to optimize vision. Neurolens offers the only prescription lenses that use a contoured prism to treat headaches, neck and shoulder pain, and eyestrain caused by eye misalignment. The company recently announced the launch of the N3, a fast and accurate way for eyecare providers to measure eye misalignment down to a fraction of a prism diopter.

The company is committed to enhancing patient outcomes and assisting eyecare providers in delivering much-needed relief to their patients, the announcement said.

"With the introduction of the N3, Neurolens will enable even more eyecare professionals to access contoured prism technology in their optometry practices," said Igor DaCruz, managing director of life sciences at Trinity. "We are thrilled to work with them as they continue changing the lives of patients."

This capital will fuel continued growth in the company's operations and is expected to further accelerate the adoption of Neurolens N3 devices in optometry practices across the U.S. and Canada.

"While we continue to experience double-digit growth each year, the unmet patient need remains immense," said Davis Corley, executive chairman of Neurolens. "We are committed to leveraging innovative technology like the N3 to remove barriers to adoption and ensure that every eyecare professional can access these life-changing outcomes for their patients. We are grateful that Trinity Capital Inc.—along with our dedicated investors—are embracing our mission to transform eyecare."